A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00038584|
Recruitment Status : Completed
First Posted : June 3, 2002
Last Update Posted : August 1, 2012
SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death.
This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Squamous Cell Cancer of Head and Neck||Drug: SCH66336||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||37 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy|
|Study Start Date :||June 1999|
|Actual Primary Completion Date :||November 2004|
|Actual Study Completion Date :||November 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00038584
|United States, Texas|
|The University of Texas M. D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|